Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PYGB | P11216 | 3/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085043 | 1.00 | LGALS8 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL4114206 | 1.00 | LGALS8 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL4114204 | 1.00 | LGALS8 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL14134610 | 0.89 | CA2 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL12085042 | 0.89 | CA2 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL12081984 | 0.89 | CA2 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL14134617 | 0.89 | CA2 (0.51) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL12767198 | 0.83 | CA2 (0.53) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL17969702 | 0.83 | CA2 (0.53) | LGALS8CA2CA9CA1ALDH1A1 | |
| SCHEMBL9233216 | 0.83 | MAPK1 (0.60) | CA2CA9CA1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| WO-2007048190-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | MICA, PICALM, CLTB | LGALS8 1262/4885CA2 3784/4885CA9 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.